HC Wainwright & Co. Reiterates Buy on Viracta Therapeutics, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on Viracta Therapeutics (NASDAQ:VIRX) and maintained a $4 price target.
March 12, 2024 | 10:20 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Robert Burns reiterated a Buy rating on Viracta Therapeutics and maintained a $4 price target.
The reiteration of a Buy rating and maintenance of a $4 price target by a reputable analyst like Robert Burns could positively influence investor sentiment towards VIRX, potentially leading to an increase in its stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100